The $1.2B Breakup That Launched a New Psychedelic Biotech

The $60 million Series A, announced March 24, 2026, was led by Satori Neuro with participation from Prime Movers Lab (which had led the original Gilgamesh's $27 million Series A back in 2021) and other institutional investors.

So what's in the pipeline? Two programs stand out.

The Oral Ketamine Rival

The most advanced asset is blixeprodil (GM-1020), an oral NMDA receptor antagonist being developed for major depressive disorder. If that sounds like alphabet soup, here's the translation: it works on the same brain pathway as ketamine, the anesthetic-turned-depression-treatment that's been generating headlines for years.

Ketamine and its FDA-approved cousin esketamine (marketed as Spravato) can lift severe depression within hours, something traditional antidepressants take weeks to do. The catch? Ketamine needs to be given intravenously or as a nasal spray in a clinical setting. Patients can't just pop a pill at home.

Blixeprodil aims to change that. It's orally bioavailable (over 60% of the drug reaches the bloodstream when swallowed), with a peak effect at about 1.5 hours and a half-life of 4.3 hours. In animal studies, the gap between the dose that treats depression and the dose that causes motor side effects was approximately 12-fold, compared to just 3-fold for ketamine. That's a much wider safety margin.

Phase 2a results were positive, showing "rapid, robust, and durable antidepressant effects." The company plans to advance blixeprodil to late-stage studies in 2026. If it works, an effective oral alternative to ketamine could be enormous, despite the condition affecting hundreds of millions of people worldwide.

The Ibogaine Problem, Potentially Solved

The second program worth watching is GM-3009, a cardio-safe ibogaine analog heading into Phase 1 studies later in 2026.

Ibogaine is a naturally occurring psychoactive substance that's shown remarkable results in treating opioid addiction and depression. The problem? It can cause fatal heart arrhythmias. That's kept it illegal or heavily restricted in most countries, despite growing anecdotal evidence of its benefits. Building a version of ibogaine that doesn't threaten to stop your heart is one of the holy grails of psychedelic-adjacent drug development.

A Crowded (and Risky) Neighborhood

Gilgamesh Pharma isn't operating in a vacuum. The neuroplastogen space (drugs that promote the brain's ability to rewire itself, often inspired by psychedelics but designed to work without the trip) is getting crowded. Enveric Biosciences is advancing EB-003 through IND-enabling studies. Reunion Neuroscience plans to file an IND for its non-psychedelic compound RE245 in 2026. Transneural Therapeutics launched in April 2025 with its own non-hallucinogenic pipeline. Even tiny Elkedonia raised an €11.25 million seed round in mid-2025.

And NMDA antagonists specifically have had a rough stretch. Neurocrine's NBI-1070, an NMDA-targeted depression drug, failed its Phase 2 trial in 2025. CNS drugs have an estimated 85% failure rate in Phase 2 and Phase 3 studies. The graveyard is well-populated.

Why This One Might Be Different

Gilgamesh Pharma has a few things going for it that most early-stage biotechs don't. First, the leadership team is stacked: Sporn previously founded Perception Neuroscience (acquired by ATAI Life Sciences), and CSO Andrew Kruegel conducted foundational research on antidepressant mechanisms while at Columbia University. CMO Gerard Marek brings 25-plus years of clinical development experience from Yale, Eli Lilly, and Pfizer.

Second, the AbbVie relationship provides both validation and ongoing collaboration revenue. When a pharma giant pays up to $1.2 billion for your lead compound, it sends a signal about the quality of your science.

Third, blixeprodil already has positive Phase 2a data. In a field where most compounds die before they ever reach patients, that's a meaningful head start.

The $60 million won't last forever, and late-stage trials are expensive. But Gilgamesh Pharma is essentially a second act written by a team that already sold the first one for a billion dollars. In biotech, that kind of track record buys you something money can't: credibility.

The Drug That Finally Cracked the Brain's Toughest Bouncer

For nearly 20 years, kids with Hunter syndrome had a treatment that couldn't reach their brains. Denali Therapeutics just got FDA approval for Avlayah, the first enzyme therapy that crosses the blood-brain barrier, and it could change the game for rare neurological diseases.